Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases -- -- ...
Inhibikase Therapeutics (IKT) appointed Mark Iwicki as the company’s CEO, replacing Milton Werner, founder of Inhibikase, effective February ...
Werner, founder of Inhibikase, effective February 14, 2025. Additionally, effective February 14, 2025, Amit Munshi, a member of the Board of Directors of the Company (the “Board”) and veteran ...
Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases -- -- Amit Munshi Appointed Chair of the Board of Directors -- BOSTON, Feb.
10d
Hosted on MSNHC Wainwright & Co. Downgrades Inhibikase Therapeutics (IKT)Fintel reports that on February 12, 2025, HC Wainwright & Co. downgraded their outlook for Inhibikase Therapeutics ...
BOSTON, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or“Company”), today announced the appointment of Mark Iwicki as the Company's Chief ...
Inhibikase Therapeutics, Inc. (NYSE:IKT – Free Report) – Equities researchers at HC Wainwright issued their Q1 2025 EPS estimates for Inhibikase Therapeutics in a research report issued on ...
Inhibikase Therapeutics is pausing work on its experimental Parkinson’s disease drug risvodetinib and seeking “strategic options” for the med after it came up short in the efficacy stakes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results